News | August 27, 2022
Jubilant receives EIR from USFDA for its radiopharmaceuticals manufacturing facility Montreal Canada
With the receipt of the EIR, the inspection stands successfully closed.
With the receipt of the EIR, the inspection stands successfully closed.
The drug is expected to cater to the fast growing Rheumatoid Arthritis, Plaque Psoriasis, JIA, Psoriatic Arthritis, Ankylosing Spondylitis, Ulcerative Colitis, Crohns disease, HS and Uveitis markets
Collaboration focuses on developing and implementing real-world research to drive patient access to cancer medicines
Plant is part of the company's CAD $30 million capital investment in the site
Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia
Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine
The drug will be manufactured at the group’s topical facility at Ahmedabad
Abevmy follows the launch of the company’s two oncology biosimilars in Canada, Ogivri (bTrastuzumab) in 2019 – the first Trastuzumab approved in the country – and Fulphila (bPegfilgrastim), which was launched in 2020
It is part of the company's CAD $30 million capital investment in the Aurora, Canada site
Onshore manufacturing facility is expected to be based in Quebec and produce up to 100 million mRNA respiratory vaccine doses annually
Subscribe To Our Newsletter & Stay Updated
